Home drugs Sprycel (Dasatinib)

Sprycel (Dasatinib)

This page contains brief information about dasatinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)          Sprycel
FDA Approved                Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Dasatinib is approved to treat:

  • Acute lymphoblastic leukemia that is Philadelphia chromosome positive. It is used in adults whose disease did not respond to other drugs or who are not able to use other drugs.
  • Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used:
    • In children with chronic phase CML.
    • In adults with chronic phase CML that is newly diagnosed.
    • In adults with chronic phase, accelerated phase, or blastic phase CML whose disease did not respond to other drugs or who are not able to use other drugs.

Dasatinib is also being studied in the treatment of other types of cancer.

More About Dasatinib

Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.

MedlinePlus Information on Dasatinib – A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.